论文部分内容阅读
目的:观察分析替莫唑胺治疗恶性胶质瘤的有效性和安全性。方法:将收集到的117例视神经胶质瘤手术患者分为观察组和对照组,分别是术后采用替莫唑胺(TMZ)联合放疗组(观察组)、单纯放疗组(对照组),两组患者均以治疗28 d为1个疗程,进行2个疗程。对患者进行随访,观察患者的无进展生存时间和总的生存时间。采用SPSS 20.0进行分析,计量资料采用t检验、计数资料应用χ2检验。结果:TMZ联合放疗的有效率为76.47%,患者平均肿瘤无进展生存时间为(10.62±4.74)月。TMZ联合放疗组无复发病例,而对照组2例视神经胶质瘤复发,TMZ联合放疗治疗后脑水肿发生率低于单独放疗治疗后脑水肿发生率(P<0.05)。结论:胶质瘤患者术后替莫唑胺联合放疗效果明显优于单独放疗治疗的效果,可延长患者的生存时间,降低肿瘤的并发症、组织水肿和肿瘤的复发率。
Objective: To observe and analyze the efficacy and safety of temozolomide in treating malignant glioma. Methods: The 117 patients with optic neuroglioma were divided into two groups: observation group and control group. The patients were treated with TMZ combined with radiotherapy (observation group), radiotherapy alone group (control group), two groups Both treated 28 days for a course of treatment, for 2 courses. Patients were followed up to observe the patient’s progression-free survival and overall survival. Using SPSS 20.0 for analysis, measurement data using t test, count data using χ2 test. Results: The effective rate of TMZ combined with radiotherapy was 76.47%, and the mean progression-free survival time of patients was (10.62 ± 4.74) months. There was no recurrence in TMZ combined with radiotherapy group, while two cases of glioma recurred in control group. The incidence of cerebral edema after TMZ combined with radiotherapy was lower than that of radiotherapy alone (P <0.05). Conclusion: The combined effect of temozolomide and radiotherapy is better than that of radiotherapy alone in patients with glioma, which can prolong the survival time of patients and reduce the complication, edema and recurrence rate.